JP2015515985A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015515985A5 JP2015515985A5 JP2015510436A JP2015510436A JP2015515985A5 JP 2015515985 A5 JP2015515985 A5 JP 2015515985A5 JP 2015510436 A JP2015510436 A JP 2015510436A JP 2015510436 A JP2015510436 A JP 2015510436A JP 2015515985 A5 JP2015515985 A5 JP 2015515985A5
- Authority
- JP
- Japan
- Prior art keywords
- laquinimod
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- multiple sclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims 19
- 229960004577 laquinimod Drugs 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 201000006417 multiple sclerosis Diseases 0.000 claims 7
- 208000024806 Brain atrophy Diseases 0.000 claims 3
- 206010061818 Disease progression Diseases 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 3
- 230000005750 disease progression Effects 0.000 claims 3
- 206010071068 Clinically isolated syndrome Diseases 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 230000006866 deterioration Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 230000006764 neuronal dysfunction Effects 0.000 claims 2
- 230000003961 neuronal insult Effects 0.000 claims 2
- 230000004112 neuroprotection Effects 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 238000011360 adjunctive therapy Methods 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000009266 disease activity Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000011294 monotherapeutic Methods 0.000 claims 1
- 230000019581 neuron apoptotic process Effects 0.000 claims 1
- 230000009223 neuronal apoptosis Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641389P | 2012-05-02 | 2012-05-02 | |
| US61/641,389 | 2012-05-02 | ||
| PCT/US2013/039090 WO2013166166A1 (en) | 2012-05-02 | 2013-05-01 | Use of high dose laquinimod for treating multiple sclerosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017141409A Division JP2017222691A (ja) | 2012-05-02 | 2017-07-21 | 多発性硬化症を治療するための高投与量ラキニモドの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015515985A JP2015515985A (ja) | 2015-06-04 |
| JP2015515985A5 true JP2015515985A5 (enExample) | 2016-06-23 |
Family
ID=49514859
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510436A Withdrawn JP2015515985A (ja) | 2012-05-02 | 2013-05-01 | 多発性硬化症を治療するための高投与量ラキニモドの使用 |
| JP2017141409A Withdrawn JP2017222691A (ja) | 2012-05-02 | 2017-07-21 | 多発性硬化症を治療するための高投与量ラキニモドの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017141409A Withdrawn JP2017222691A (ja) | 2012-05-02 | 2017-07-21 | 多発性硬化症を治療するための高投与量ラキニモドの使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20130303569A1 (enExample) |
| EP (1) | EP2844255A4 (enExample) |
| JP (2) | JP2015515985A (enExample) |
| KR (1) | KR20150013658A (enExample) |
| CN (2) | CN105832733A (enExample) |
| AR (1) | AR090885A1 (enExample) |
| AU (1) | AU2013256352A1 (enExample) |
| BR (1) | BR112014027010A2 (enExample) |
| CA (1) | CA2870684A1 (enExample) |
| CL (1) | CL2014002935A1 (enExample) |
| EA (1) | EA201492010A1 (enExample) |
| HK (1) | HK1206246A1 (enExample) |
| IL (1) | IL235337A0 (enExample) |
| MX (1) | MX2014013039A (enExample) |
| PE (1) | PE20150161A1 (enExample) |
| PH (1) | PH12014502447A1 (enExample) |
| SG (1) | SG11201406594UA (enExample) |
| TW (2) | TW201804997A (enExample) |
| UY (1) | UY34775A (enExample) |
| WO (1) | WO2013166166A1 (enExample) |
| ZA (1) | ZA201408820B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013055907A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| AU2013214909A1 (en) | 2012-02-03 | 2014-09-18 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNFa therapy |
| AR090073A1 (es) | 2012-02-16 | 2014-10-15 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos |
| US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| CA2884272A1 (en) * | 2012-10-12 | 2014-04-17 | Giancarlo Comi | Laquinimod for reducing thalamic damage in multiple sclerosis |
| KR20150091077A (ko) | 2012-11-07 | 2015-08-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드의 아민염 |
| JP2016510343A (ja) * | 2013-02-15 | 2016-04-07 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドを用いる多発性硬化症の治療 |
| EP2970129A2 (en) | 2013-03-14 | 2016-01-20 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| AR098924A1 (es) * | 2013-12-23 | 2016-06-22 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida |
| SG11201608674UA (en) * | 2014-04-29 | 2016-11-29 | Teva Pharma | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| WO2017027512A1 (en) * | 2015-08-13 | 2017-02-16 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to treat traumatic brain injury |
| US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
| TWI879737B (zh) * | 2018-07-20 | 2025-04-11 | 德商馬克專利公司 | 利用經取代胺基-嘧啶化合物治療及預防多發性硬化症之方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| HRP20160455T1 (hr) * | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| US20080118553A1 (en) * | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| BR112012000568A2 (pt) * | 2009-06-19 | 2015-10-06 | Teva Pharma | tratamento da esclerose múltipla com laquinimod |
| EP2523668A1 (en) * | 2010-01-13 | 2012-11-21 | Ramot at Tel-Aviv University Ltd | Treatment of multiple sclerosis |
| WO2013055907A1 (en) * | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| JP2016510343A (ja) * | 2013-02-15 | 2016-04-07 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドを用いる多発性硬化症の治療 |
-
2013
- 2013-04-29 AR ARP130101459A patent/AR090885A1/es unknown
- 2013-04-29 TW TW106117959A patent/TW201804997A/zh unknown
- 2013-04-29 TW TW102115308A patent/TW201347762A/zh unknown
- 2013-04-30 UY UY0001034775A patent/UY34775A/es not_active Application Discontinuation
- 2013-05-01 WO PCT/US2013/039090 patent/WO2013166166A1/en not_active Ceased
- 2013-05-01 KR KR1020147033707A patent/KR20150013658A/ko not_active Withdrawn
- 2013-05-01 SG SG11201406594UA patent/SG11201406594UA/en unknown
- 2013-05-01 EP EP13784231.6A patent/EP2844255A4/en not_active Withdrawn
- 2013-05-01 BR BR112014027010A patent/BR112014027010A2/pt not_active IP Right Cessation
- 2013-05-01 US US13/874,537 patent/US20130303569A1/en not_active Abandoned
- 2013-05-01 AU AU2013256352A patent/AU2013256352A1/en not_active Abandoned
- 2013-05-01 MX MX2014013039A patent/MX2014013039A/es unknown
- 2013-05-01 JP JP2015510436A patent/JP2015515985A/ja not_active Withdrawn
- 2013-05-01 CA CA2870684A patent/CA2870684A1/en not_active Abandoned
- 2013-05-01 CN CN201610240473.8A patent/CN105832733A/zh active Pending
- 2013-05-01 HK HK15106789.5A patent/HK1206246A1/xx unknown
- 2013-05-01 CN CN201380022530.XA patent/CN104284663A/zh active Pending
- 2013-05-01 PE PE2014001911A patent/PE20150161A1/es not_active Application Discontinuation
- 2013-05-01 EA EA201492010A patent/EA201492010A1/ru unknown
-
2014
- 2014-10-26 IL IL235337A patent/IL235337A0/en unknown
- 2014-10-29 CL CL2014002935A patent/CL2014002935A1/es unknown
- 2014-10-31 PH PH12014502447A patent/PH12014502447A1/en unknown
- 2014-12-02 ZA ZA2014/08820A patent/ZA201408820B/en unknown
-
2015
- 2015-06-05 US US14/731,971 patent/US20150265592A1/en not_active Abandoned
- 2015-09-15 US US14/854,849 patent/US20160000775A1/en not_active Abandoned
-
2017
- 2017-07-21 JP JP2017141409A patent/JP2017222691A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015515985A5 (enExample) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2013155188A5 (enExample) | ||
| RU2014109074A (ru) | ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| JP2012193216A5 (enExample) | ||
| JP2015505564A5 (enExample) | ||
| JP2015515475A5 (enExample) | ||
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| JP2015512406A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| JP2013541583A5 (enExample) | ||
| JP2018520189A5 (enExample) | ||
| FI3801536T3 (fi) | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi | |
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| JP2013518124A5 (enExample) | ||
| JP2017510607A5 (enExample) | ||
| JP2016507500A5 (enExample) | ||
| JP2014508758A5 (enExample) | ||
| JP2016510343A5 (enExample) | ||
| JP2019513814A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JP2011500589A5 (enExample) | ||
| FI3352735T3 (fi) | Pitkitetysti vapauttavia olantsapiiniformulaatioita | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами |